Gena Wang
Stock Analyst at Barclays
(3.24)
# 1,092
Out of 5,122 analysts
240
Total ratings
44.59%
Success rate
2.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Assumes: Overweight | $87 | $64.73 | +34.40% | 6 | Jan 28, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $24.80 | +101.61% | 7 | Nov 24, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $94 → $90 | $16.66 | +440.22% | 7 | Nov 13, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $9.49 | +247.73% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $42.20 | -40.76% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $13.05 | +7.28% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.39 | +156.41% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $74.83 | -9.13% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $20.28 | -1.38% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $465.61 | -11.08% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $6.54 | +37.61% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $6.70 | +34.33% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $351.80 | +49.80% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $84.59 | +12.31% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $57.61 | +38.86% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $3.53 | +126.63% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $24.03 | -29.26% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $10.86 | +240.70% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $59 → $62 | $72.93 | -14.99% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $52.00 | +7.69% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $27.89 | -24.70% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $7.68 | +303.65% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.06 | +45.63% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $23.44 | -61.60% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $7.32 | +241.53% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.02 | +124.58% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $7.10 | +26.76% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.27 | +5,118.22% | 1 | Jan 6, 2017 |
Cytokinetics
Jan 28, 2026
Assumes: Overweight
Price Target: $87
Current: $64.73
Upside: +34.40%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $24.80
Upside: +101.61%
Legend Biotech
Nov 13, 2025
Maintains: Overweight
Price Target: $94 → $90
Current: $16.66
Upside: +440.22%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $9.49
Upside: +247.73%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $42.20
Upside: -40.76%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $13.05
Upside: +7.28%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.39
Upside: +156.41%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $74.83
Upside: -9.13%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $20.28
Upside: -1.38%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $465.61
Upside: -11.08%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $6.54
Upside: +37.61%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $6.70
Upside: +34.33%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $351.80
Upside: +49.80%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $84.59
Upside: +12.31%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $57.61
Upside: +38.86%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $3.53
Upside: +126.63%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $24.03
Upside: -29.26%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $10.86
Upside: +240.70%
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $72.93
Upside: -14.99%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $52.00
Upside: +7.69%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $27.89
Upside: -24.70%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $7.68
Upside: +303.65%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.06
Upside: +45.63%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $23.44
Upside: -61.60%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $7.32
Upside: +241.53%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.02
Upside: +124.58%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $7.10
Upside: +26.76%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.27
Upside: +5,118.22%